BridgeBio Pharma, Inc. (BBIO) Q3 2025 10-Q Quarterly Report
BridgeBio Pharma, Inc. (BBIO) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 29, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
BridgeBio Pharma, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New regulatory risk: FDA’s 2025 increased scrutiny of DTC advertising, including untitled letter received for Attruby ad
- • Updated operational risk: ongoing FDA staffing cuts and leadership departures causing review delays and regulatory uncertainties
BridgeBio Pharma, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$121M
▲ +4318.0% YoY▲ +9.2% QoQ
Net Income
-$183M
▼ -12.8% YoY▼ -0.5% QoQ
Operating Margin
-120.3%
▲ +689837bp YoY▲ +115bp QoQ
Net Margin
-151.4%
▲ +577978bp YoY▲ +1312bp QoQ
ROE
9.5%
Total Assets
$998M
EPS (Diluted)
$-0.95
▼ -9.2% YoY▲ +1.0% QoQ
Operating Cash Flow
-$110M
▲ +39.3% YoY▼ -35.8% QoQ
Source: XBRL data from BridgeBio Pharma, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on BridgeBio Pharma, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.